Thailand Institute of Nuclear Technology gets cyclotron complex with radiochemical lab

The facility will be located at Ongkharak Nuclear Research Centre in Nakhon Nayok.

The State Atomic Energy Corporation ROSATOM (Russia) and Kinetics Corporation Ltd. (Thailand) will supply a cyclotron complex with radiochemical laboratories for the Thailand Institute of Nuclear Technology (TINT). Following the results of the procurement procedure conducted by TINT, Kinetics Corporation, with its offer based on ROSATOM’s technologies, was awarded a turn-key contract. RUSATOM Healthcare, a subsidiary of ROSATOM, will act as the technology provider.

The facility will be located at Ongkharak Nuclear Research Centre in Nakhon Nayok. With an area of more than 5400 m2, the new complex will accommodate a cyclotron and several laboratories for the production of radiopharmaceuticals for nuclear medicine and other purposes, as well as serve as a platform for R&D activities in the field of radiation technologies and innovations.

Currently all the isotopes for SPECT in Thailand are imported, with some PET isotopes produced in hospitals locally in amounts that cannot satisfy the demand. Thus, the new cyclotron supplied by ROSATOM will allow Thailand to produce its own isotopes to save lives and help to boost innovations in the country. The project will also drive the R&D activities in nuclear medicine, as well as in application of nuclear technologies in the different areas of industry.

“We are grateful to our Thai partners and the customer for the trust in the Russian nuclear technologies. ROSATOM has more than 70 years of expertise in innovations, including designing and manufacturing nuclear medicine solutions, with 14 radionuclide production facilities operating in Russia”, said Egor Simonov, Head of ROSATOM Southeast Asia.

The core of the complex will be a MCC-30/15 cyclotron of 30 MeV proton energy, supplied by ROSATOM. It will be utilized also to produce isotopes for PET and SPECT diagnostics. These isotopes allow determining the stage of oncological, cardiac, and neurological diseases accurately, and in many cases may be almost the only way to prescribe appropriate treatment.